Live Analyst Rating Changes 29681 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Charles Rhyee
TD

Charles Rhyee

TD Cowen
Wall Street Analyst
★★★★☆
#801
on 13Foresight · ranked by our own returns
61%
Success Rate
+7.1%
Average Return
47 of 77 calls profitable · +2.3% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 61% of Charles Rhyee's ratings turned a profit when each position was held for 1 year — averaging +7.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

103 Buy 33 Hold 2 Sell
Charles's Stock Coverage 38 ratings · 2026-09-02
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VEEV
Veeva Systems
 Aug 27, 2026 BUY Buy
-2.3% avg upside
38 analysts
$283.00
1.30% Upside
 -1.4% ·
CVS
CVS Health
 Aug 26, 2026 BUY Strong Buy
+10.4% avg upside
39 analysts
$110.00
12.66% Upside
 +3.8% ·
BTSG
BrightSpring Health Services, Inc.
 Aug 19, 2026 BUY Strong Buy
+11.1% avg upside
20 analysts
$81.00
36.96% Upside
 -0.3% ·
EVH
Evolent Health
 Aug 17, 2026 BUY Strong Buy
+126.6% avg upside
19 analysts
$6.00
40.10% Upside
 +2.0% ·
CAH
Cardinal Health
 Aug 13, 2026 BUY Strong Buy
-12.5% avg upside
30 analysts
$280.00
17.06% Upside
 +1.5% ·
DRIO
DarioHealth
 Aug 12, 2026 HOLD Strong Buy
+21.8% avg upside
6 analysts
$8.00
13.94% Upside
 -2.4% ·
GDRX
GoodRx Holdings
 Aug 11, 2026 BUY Buy
+271.3% avg upside
28 analysts
$5.00
44.45% Upside
 -7.1% ·
MDLN
Medline
 Aug 10, 2026 BUY Strong Buy
+32.6% avg upside
27 analysts
$45.00
28.16% Upside
 +7.4% ·
CRL
Charles River Labs
 Aug 10, 2026 BUY Strong Buy
-17.5% avg upside
35 analysts
$300.00
6.18% Upside
 +7.0% ·
COR
Cencora
 Aug 09, 2026 BUY Buy
-3.3% avg upside
45 analysts
$400.00
20.81% Upside
 +3.7% ·
MCK
McKesson
 Aug 06, 2026 BUY Strong Buy
-15.7% avg upside
29 analysts
$1006.00
10.86% Upside
 +2.5% ·
AMWL
American Well
 Aug 05, 2026 HOLD Hold
+29.3% avg upside
15 analysts
$12.00
0.56% Downside
 -9.8% ·
FTRE
Fortrea Holdings Inc.
 Aug 04, 2026 BUY Buy
+14.9% avg upside
12 analysts
$23.00
29.79% Upside
 +4.8% ·
TDOC
Teladoc
 Aug 03, 2026 HOLD Buy
+359.4% avg upside
38 analysts
$6.00
4.10% Downside
 -2.7% ·
WAY
Waystar Holding Corp.
 Aug 03, 2026 BUY Strong Buy
+44.1% avg upside
30 analysts
$42.00
63.01% Upside
 +15.5% ·
ICLR
Icon
 Aug 03, 2026 BUY Strong Buy
+16.7% avg upside
26 analysts
$197.00
22.10% Upside
 +1.9% ·
OPCH
Option Care Health
 Aug 02, 2026 HOLD Strong Buy
+23.9% avg upside
20 analysts
$23.00
2.69% Downside
 +0.4% ·
IQV
IQVIA Holdings
 Jul 29, 2026 BUY Strong Buy
-5.6% avg upside
39 analysts
$288.00
11.57% Upside
 +6.0% ·
MEDP
Medpace Holdings
 Jul 23, 2026 HOLD Buy
-17.2% avg upside
17 analysts
$492.00
15.56% Downside
 -2.1% ·
MDRX
Veradigm
 May 27, 2026 BUY Strong Buy
+205.0% avg upside
22 analysts
$8.00
66.51% Upside
 -1.8% ·
CI
Cigna
 May 04, 2026 BUY Strong Buy
+22.2% avg upside
29 analysts
$338.00
19.32% Upside
 -0.6% ·
OWLT
Owlet
 Nov 13, 2025 BUY Strong Buy
+139.4% avg upside
11 analysts
$15.00
207.40% Upside
 -50.9% ·
KMPR
Kemper
 Jun 11, 2025 BUY Hold
+111.4% avg upside
8 analysts
$90.00
225.45% Upside
 -59.3% ·
W
Wayfair
 Jun 05, 2025 BUY Buy
+25.4% avg upside
55 analysts
$51.00
45.77% Downside
 +52.2% ·
XNCR
Xencor
 Sep 09, 2024 BUY Strong Buy
+25.6% avg upside
27 analysts
 — -58.2% ·
HLTHQ
Cue Health
 Mar 15, 2024 HOLD Hold
2 analysts
 — · ·
CVX
Chevron
 Oct 30, 2023 BUY Strong Buy
-11.6% avg upside
44 analysts
$170.00
19.54% Downside
 +5.7% ·
BTTX
Better Therapeutics
 Dec 12, 2022 BUY Strong Buy
+1499900.1% avg upside
3 analysts
 — · ·
MDVLQ
MedAvail Holdings
 Aug 16, 2022 BUY Strong Buy
+224999900.1% avg upside
2 analysts
$250.00
249999900.09% Upside
 · ·
OTRKQ
Ontrak
 May 17, 2022 SELL Hold
+21716566.7% avg upside
7 analysts
$1.30
1299899.97% Upside
 · ·
UNH
UnitedHealth
 Apr 16, 2021 BUY Strong Buy
+14.8% avg upside
36 analysts
$415.00
4.79% Upside
 +38.6% ·
ELV
Elevance Health
 Apr 14, 2021 BUY Strong Buy
+11.7% avg upside
33 analysts
$395.00
1.90% Downside
 +44.1% ·
OSCR
Oscar Health
 Mar 29, 2021 HOLD Buy
-26.7% avg upside
16 analysts
$29.00
2.68% Downside
 -59.7% ·
CNC
Centene
 Feb 08, 2021 BUY Buy
+9.2% avg upside
29 analysts
$80.00
22.62% Upside
 +47.1% ·
HUM
Humana
 Feb 01, 2021 HOLD Buy
+6.3% avg upside
34 analysts
$460.00
16.57% Upside
 +3.5% ·
MOH
Molina Healthcare
 Jun 16, 2020 BUY Buy
+16.2% avg upside
26 analysts
$210.00
3.51% Upside
 +40.9% ·
OMCL
Omnicell
 Oct 30, 2015 HOLD Strong Buy
+42.0% avg upside
12 analysts
$29.00
16.00% Downside
 +19.9% ·
ATHM
AutoHome
 Feb 25, 2014 BUY Buy
+44.0% avg upside
15 analysts
$42.00
90.03% Upside
 +7.4% ·
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Charles Rhyee — Frequently Asked Questions
How accurate are Charles Rhyee's stock ratings?
Based on the calls 13Foresight could measure, about 58% of Charles's ratings were profitable over a one-year hold, with an average return of +7.1% per rating, or +2.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Charles ranked on 13Foresight?
Charles Rhyee is currently ranked #801 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Charles cover?
Charles most recently has ratings on VEEV, CVS, BTSG, EVH, CAH, DRIO, GDRX, MDLN, CRL, COR, MCK, AMWL and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.